Currently, there are 972.45M common shares owned by the public and among those 690.88M shares have been available to trade.
The company’s stock has a 5-day price change of -1.54% and -7.90% over the past three months. MNST shares are trading -6.35% year to date (YTD), with the 12-month market performance down to -14.03% lower. It has a 12-month low price of $43.32 and touched a high of $61.22 over the same period. MNST has an average intraday trading volume of 5.42 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.90%, -6.80%, and -4.79% respectively.
Institutional ownership of Monster Beverage Corp (NASDAQ: MNST) shares accounts for 65.54% of the company’s 972.45M shares outstanding.
It has a market capitalization of $47.87B and a beta (3y monthly) value of 0.74. The stock’s trailing 12-month PE ratio is 31.62, while the earnings-per-share (ttm) stands at $1.56. The company has a PEG of 3.09 and a Quick Ratio of 2.51 with the debt-to-equity ratio at 0.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.30% over the week and 1.97% over the month.
Analysts forecast that Monster Beverage Corp (MNST) will achieve an EPS of 0.4 for the current quarter, 0.46 for the next quarter and 1.87 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.38 while analysts give the company a high EPS estimate of 0.38. Comparatively, EPS for the current quarter was 0.35 a year ago. Earnings per share for the fiscal year are expected to increase by 6.44%, and 12.78% over the next financial year. EPS should shrink at an annualized rate of 10.22% over the next five years, compared to 11.87% over the past 5-year period.
Looking at the support for the MNST, a number of firms have released research notes about the stock. Exane BNP Paribas stated their Underperform rating for the stock in a research note on December 19, 2024, with the firm’s price target at $46-$45. Argus was of a view on November 12, 2024 that the stock is Buy, while TD Cowen gave the stock Hold rating on November 11, 2024, issuing a price target of $50- $55. UBS on their part issued Neutral rating on November 08, 2024.
